SGLT2 inhibitors and cardiovascular outcomes in heart failure with mildly reduced and preserved ejection fraction: A systematic review and meta-analysis
Source : https://www.sciencedirect.com/science/article/pii/S0019483223000433?via=ihub
Available online 11 March 2023 Author links open overlay panel Mainak Banerjee a 1 , Rimesh Pal b 1 , Kirthana Nair b , Satinath Mukhopadhyay a Show more To...
Conclusions: This meta-analysis established the place of SGLT2i as a foundational therapy among patients with HF with preserved and mildly reduced EF regardless of diabetes.
Recency of Heart Failure Hospitalization, Outcomes, and the Effect of Empagliflozin: An EMPEROR-Pooled Analysis
Source : https://www.sciencedirect.com/science/article/pii/S2213177923000732?via=ihub
Available online 20 February 2023 Author links open overlay panel a b c , , d e , , , , , , , k l , m n Show...
Conclusions: Patients with a recent HF hospitalization have a high risk of events. Empagliflozin reduced HF events regardless of HF hospitalization recency.
Clinical Study of Metabolic Parameters, Leptin and the SGLT2 Inhibitor Empagliflozin among Patients with Obesity and Type 2 Diabetes - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36901837/
Obesity is a major public health problem worldwide, and it is associated with many diseases and abnormalities, most importantly, type 2 diabetes. The visceral adipose tissue produces an immense variety...
Lessons learned: The EMMY trial shows that early use of the SGLT2 inhibitor empagliflozin after acute myocardial infarction (MI) improves natriuretic peptide levels and markers of cardiac function and structure supporting the use of Empagliflozin in HF related to a recent MI.
Metformin, Empagliflozin, and Their Combination Modulate Ex-Vivo Macrophage Inflammatory Gene Expression - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36902218/
Type-2 Diabetes Mellitus is a complex, chronic illness characterized by persistent high blood glucose levels. Patients can be prescribed anti-diabetes drugs as single agents or in combination depending on the...
Conclusions/Relevance: Findings from this study suggest that metformin and empagliflozin as single agents or in combination can directly modulate inflammatory gene expression in macrophages and upregulate the expression of their receptors.
Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Reduced Trial
Source : https://www.sciencedirect.com/science/article/pii/S2213177922007090?via=ihub
There is limited published information on outcome adjudication in heart failure (HF).The authors sought to compare investigator reports (IRs) to a Cli...
Conclusions: Investigator adjudication is an alternative to a CEC with similar accuracy and faster event accumulation. The use of granular (SCTI) criteria did not improve trial performance. Finally, our data suggest that consideration be given to broadening the HHF definition to include “for or with” worsening disease.
-
Cardiologist Connect3yrKey Points • Source: JACC Heart Failure • Conclusion: “In this study, the investigators had a similar accuracy in detecting treatment effect and HHF [first event hospitalization primarily for heart failure] events with comparable Show More
Clinical profiling of end-stage heart failure with preserved ejection fraction: The National Readmission Database
Source : https://www.internationaljournalofcardiology.com/article/S0167-5273(23)00269-3/fulltext
Heart failure with preserved ejection is a heterogenous clinical syndrome with varying prognosis. * Using unsupervised machine learning algorithm, 4 clinical profiles were identified. 1) obese patients with sleep and...
Conclusion: End-stage HFpEF presents with different clinical profiles with varied upstream causes. This may help provide evidence toward the development of targeted therapies.
Atrial Fibrillation Ablation for Heart Failure With Preserved Ejection Fraction: A Randomized Controlled Trial
Source : https://www.sciencedirect.com/science/article/abs/pii/S2213177923000379?via=ihub
Patients with heart failure with preserved ejection fraction (HFpEF) frequently develop atrial fibrillation (AF). There are no randomized trials exami...
Conclusions: AF ablation improves invasive exercise hemodynamic parameters, exercise capacity, and quality of life in patients with concomitant AF and HFpEF.
Epicardial adipose tissue density is a better predictor of cardiometabolic risk in HFpEF patients: a prospective cohort study - Cardiovascular Diabetology
Source : https://cardiab.biomedcentral.com/articles/10.1186/s12933-023-01778-8
Background Epicardial adipose tissue (EAT) accumulation is associated with multiple cardiometabolic risk factors and prognosis of heart failure with preserved ejection fraction (HFpEF). The correlation between EAT density and cardiometabolic...
Conclusions: EAT density was an independent impact factor of cardiometabolic risk in HFpEF. EAT density might have better predictive value than EAT volume for metabolic syndrome and it might have prognostic value in patients with HFpEF.
Meaning: Results suggest that adding SGLT2-I therapy is intermediate or low value in patients with heart failure with preserved ejection fraction.
Distinct associations between post-discharge cognitive change patterns and 1-year outcomes in patients hospitalized for heart failure
Source : https://www.onlinejcf.com/article/S1071-9164(23)00035-0/fulltext
Among the patients hospitalized for HF who experienced cognitive impairment before discharge, 48.5% had transient cognitive impairment at 1 month after discharge. Among patients with normal cognition before discharge, 13.8%...
Conclusions: Acute HF substantially affects short-term cognition. Patients who have developed new-onset cognitive impairment have an increased risk of adverse outcomes. Monitoring cognition is necessary, particularly in high-risk patients.
Global trends in research on oxidative stress related to heart failure from 2012 to 2021: a bibliometric analysis and suggestion to researchers
Source : https://atm.amegroups.com/article/view/108849/html
Key findings * This study clarify the research focus and development trends of oxidative stress related to HF in the past decade. What is known and what is new? *...
Conclusions: Our research shows the research focus and development trends of oxidative stress related to HF in the past decade. Understanding the most important indicators of oxidative stress related to HF and the hot spots in the field of oxidative stress research related to HF can assist scholars, countries and policy-makers in the field in...
Global historical retrospect and future prospects on biomarkers of heart failure: A bibliometric analysis and science mapping
Heart failure is a rapidly growing public health problem and has become a major cause of hospitalization in middle-aged and older adults. Biomarkers are clinically important in managing heart failure...
Conclusions: Extensive national and inter-institutional collaboration should be enhanced to bridge the gap between developed and less developed countries in heart failure biomarkers research. The research in this field seems to have reached a relatively mature stage, with a decrease in research fervor in recent years. The study of the...
Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36681210/
SGLT2i significantly reduce the combined risk of HF hospitalization or cardiovascular mortality among patients with HF and LVEF >40%. However, younger patients, racial minorities, and patients from Asia did not...
Conclusion: Studies showed that empagliflozin and dapagliflozin reduce the combined risk of CV death or HHF in patients with HFmrEF and HFpEF when added to a standard HF regimen. Given that benefit has now been demonstrated across the spectrum of HF, SGLT-2Is should be considered one of the standard HF pharmacotherapy.
Acute Biomechanical Effects of Empagliflozin on Living Isolated Human Heart Failure Myocardium - Cardiovascular Drugs and Therapy
Source : https://link.springer.com/article/10.1007/s10557-023-07434-3
Purpose Multiple randomized controlled trials have presented SGLT2 inhibitors (SGLT2i) as novel pharmacological therapy for patients with heart failure, resulting in reductions in hospitalization for heart failure and mortality. Given...
Conclusion: The addition of empagliflozin to LMS from end-stage heart failure patients cultured in a biomimetic system improves contraction and relaxation kinetics by increasing total contraction duration without diminishing maximum force production. Therefore, we present convincing evidence that SGLT2i can directly act on the myocardium in...
Oral empagliflozin-loaded tri-layer core-sheath fibers fabricated using tri-axial electrospinning: Enhanced in vitro and in vivo antidiabetic performance
Source : https://www.sciencedirect.com/science/article/abs/pii/S0378517323001369?via=ihub
Empagliflozin-loaded PCL/PLA/PMMA nanofibers (EMF) were produced by tri-axial ES. * The expression of glucokinase and GLUT-2 was increased by EMF in the rat β-cell line. * The bioavailability was improved...
Relevance: EMF is suggested as an unprecedented and promotive treatment approach for T2DM with a higher bioavailability and better antidiabetic effect compared to conventional dosage forms.
Empagliflozin and renal sodium-hydrogen exchange in healthy subjects
Source : https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgad088/7041118?login=false
AbstractContext. Sodium glucose co-transporter-2 inhibitors (SGLT2i) exert clinically relevant cardiorenal protection. Among several mechanisms, inhibition of t
Conclusions: In healthy young volunteers, empagliflozin acutely increases urinary pH while inducing a substrate shift towards lipid utilization and ketogenesis, without significant changes in renal NHE3 protein expression.
Angiotensin pathways under therapy with empagliflozin in patients with chronic heart failure - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36782339/
Our data indicate that empagliflozin might lead to an activation of both the Ang I-ACE-Ang II receptor axis and the Mas-axis pathway. Activation of the Ang I-ACE-Ang II receptor axis...
Conclusions: Our data indicate that empagliflozin might lead to an activation of both the Ang I-ACE-Ang II receptor axis and the Mas-axis pathway. Activation of the Ang I-ACE-Ang II receptor axis and the protective Mas-axis pathway after initiating treatment with empagliflozin was only seen in patients with ARB co-medication, in contrast to...
-
Heart Failure Connect3yrKey Points • Source: ESC Heart Failure • Conclusions/Relevance: “Our data indicate that empagliflozin might lead to an activation of both the Ang I–ACE–Ang II receptor axis and the Mas-axis pathway. Activation of the Show More
Combining Three Independent Pathological Stressors Induces a Heart Failure with Preserved Ejection Fraction Phenotype - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36763506/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions: The 3-Hit mouse model induced a reliable HFpEF phenotype with CM hypertrophy, cardiac fibrosis, and increased M2 macrophage population. This model could be used for identifying and preclinical testing of novel therapeutic strategies.
Empagliflozin suppressed cardiac fibrogenesis through sodium-hydrogen exchanger inhibition and modulation of the calcium homeostasis - Cardiovascular Diabetology
Source : https://cardiab.biomedcentral.com/articles/10.1186/s12933-023-01756-0
Background The novel sodium-glucose co-transporter 2 inhibitor (SGLT2i) potentially ameliorates heart failure and reduces cardiac arrhythmia. Cardiac fibrosis plays a pivotal role in the pathophysiology of HF and atrial myopathy,...
Conclusions: By inhibiting NHE, empagliflozin decreases the expression of phosphorylated PLC and IP3 production, thereby reducing ER Ca2 release, extracellular Ca2 entry and the profibrotic activities of atrial fibroblasts.
Empagliflozin in Adults with Chronic Kidney Disease (CKD): Current Evidence and Place in Therapy
Hyperfiltration is the driving force that leads nephrons to glomerulosclerosis and eventually results in chronic kidney disease (CKD) and end-stage kidney disease (ESKD). It has therefore been intuitive that decreasing...
Conclusion: Empagliflozin is the latest SGLT2i drug to show proven benefits in both hyperglycemia, CV disease, heart failure, and now CKD progression. The new EMPA-KIDNEY data proves that it provides benefits in patients with and without diabetes and can be used in those with eGFR down to 20 mL/min/1.73m2. The medication is further solidified...